HepaRegeniX reports positive topline results of its Phase 1 Clinical ...
HepaRegeniX announced positive Phase 1 trial results for HRX-0215, a MKK4 inhibitor, showing it's safe and well-tolerated in healthy volunteers. The trial, involving 48 participants, confirmed HRX-0215's potential in liver regeneration without adverse effects. HepaRegeniX plans Phase 2 trials to further explore its therapeutic benefits for liver diseases.
Reference News
HepaRegeniX reports positive topline results of its Phase 1 Clinical ...
HepaRegeniX announced positive Phase 1 trial results for HRX-0215, a MKK4 inhibitor, showing it's safe and well-tolerated in healthy volunteers. The trial, involving 48 participants, confirmed HRX-0215's potential in liver regeneration without adverse effects. HepaRegeniX plans Phase 2 trials to further explore its therapeutic benefits for liver diseases.